Concord Drugs Ltd - 538965 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Nagi Reddy Concord Drugs Ltd - 538965 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vundela Ramasubba Reddy Concord Drugs Ltd - 538965 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Nagi Reddy Concord Drugs Ltd - 538965 - Resubmission of Standalone Financial Results for June 30, 2021
Concord Drugs Ltd has informed BSE regarding "Resubmission of Standalone Financial Results for the period ended June 30, 2021". Concord Drugs Ltd - 538965 - Shareholding for the Period Ended September 30, 2021
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here Concord Drugs Ltd - 538965 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate u/r 74(5) of SEBI (DP) Regulations, 2018 Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Jyoti GoelDesignation :- Company Secretary and Compliance Officer Concord Drugs Ltd - 538965 - Un-Audited Financial Results For The Quarter Ended 30.09.2021
Un-audited financial results for the quarter ended 30.09.2021 Concord Drugs Ltd - 538965 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Nagi Reddy Concord Drugs Ltd - 538965 - Board Meeting Intimation for Intimation Of Board Meeting For Consideration Of Un-Audited Financial Results For The Quarter Ended 30.09.2021
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/10/2021 ,inter alia, to consider and approve un-audited financial results for the quarter ended 30.09.2021